Thomas L Hunt
Overview
Explore the profile of Thomas L Hunt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
318
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bundrant L, Hunt T, Banks P, Gopinathan S, Boehm K, Kassler-Taub K, et al.
Clin Ther
. 2021 Jun;
43(6):1029-1050.
PMID: 34108079
Purpose: For neuropathic pain, current therapies do not provide relief for most patients; less than half achieve a 50% pain reduction. Current analgesics have adverse effects. We present 2 Phase...
2.
Hunt T, Tzanis E, Bai S, Manley A, Chitra S, McGovern P
Eur J Drug Metab Pharmacokinet
. 2020 Nov;
46(1):85-92.
PMID: 33180250
Background: Omadacycline is a semisynthetic aminomethylcycline antibacterial derived from the tetracycline class. It is approved in the USA to treat adults with acute bacterial skin and skin-structure infections and community-acquired...
3.
Bonifacio L, Hunt T, McIntyre G, Dove L, Covington P
Clin Pharmacol Drug Dev
. 2018 Apr;
7(7):727-736.
PMID: 29659201
This study evaluated the effects of eluxadoline, a mixed μ-opioid receptor (OR) and κ-OR agonist and δ-OR antagonist, on cardiac repolarization. This evaluator-blinded, placebo- and positive-controlled, 4-period crossover study randomized...
4.
Kosoglou T, Hunt T, Xuan F, Kumar B, Statkevich P, Hanson M, et al.
Clin Pharmacol Drug Dev
. 2016 Apr;
3(1):18-24.
PMID: 27128226
In a randomized, double-blind (vorapaxar and placebo), placebo- and positive-controlled (moxifloxacin 400 mg) parallel group study, the effect of single-dose vorapaxar 120 mg on QT/QTc interval was assessed in 120...
5.
Hafkin B, Kaplan N, Hunt T
Future Microbiol
. 2015 Sep;
10(11):1805-13.
PMID: 26357940
Aims: AFN-1252 is a novel inhibitor of FabI, an essential enzyme in Staphylococcus spp. This study was undertaken to assess the safety, tolerability and pharmacokinetic properties of AFN-1252, following oral...
6.
Zuo P, Haberer L, Fang L, Hunt T, Ridgway D, Russo M
J Clin Pharmacol
. 2014 May;
54(11):1221-9.
PMID: 24782199
Prolongation of the QT interval has been observed with ondansetron and other members of the 5-HT3 antagonist class. This is the first thorough QTc study of ondansetron conducted in accordance...
7.
Yu C, Campbell S, Zhu B, Knadler M, Small D, Sponseller C, et al.
Curr Med Res Opin
. 2011 Dec;
28(2):187-94.
PMID: 22149769
Objective: Statins have been shown to impact international normalized ratio (INR) when coadministered with warfarin. The aim of this study was to assess the effect of pitavastatin compared with rosuvastatin...
8.
Kovarik J, Slade A, Riviere G, Neddermann D, Maton S, Hunt T, et al.
Br J Clin Pharmacol
. 2008 May;
66(2):199-206.
PMID: 18507656
Aims: The authors determined whether intravenous atropine can prevent or counteract the negative chronotropic effect of the immunomodulator fingolimod. Methods: In this randomized, placebo-controlled, two-period, crossover study, 12 healthy subjects...
9.
Kovarik J, Riviere G, Neddermann D, Maton S, Hunt T, Schmouder R
J Clin Pharmacol
. 2008 Jan;
48(3):303-10.
PMID: 18218783
The sphingosine-1-phosphate receptor modulator fingolimod (FTY720) elicits a negative chronotropic effect at treatment initiation that attenuates thereafter. The authors determined whether isoproterenol can counteract this effect. In this randomized, crossover...
10.
Schwartz J, Agrawal N, Hartford A, Cote J, Hunt T, Verbesselt R, et al.
J Clin Pharmacol
. 2007 Apr;
47(5):620-7.
PMID: 17442687
The effects of etoricoxib on pharmacodynamic and pharmacokinetic parameters of warfarin were determined in healthy men and women. Subjects titrated with warfarin to an international normalized ratio for prothrombin time...